Immune Responses to COVID-19 Vaccination in Lymphoma Patients

University Hospital Southampton NHS Foundation Trust592 enrolled

Overview

This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in vaccinated individuals. To do this, we will collect peripheral blood from patients with lymphoid cancers before and after their COVID-19 vaccination. The blood will be explored in the laboratory for antibodies to SARS-CoV-2 and T-cell responses to the spike protein. Detailed clinical information will also be collated on about their cancer and treatment.

Study Type

OBSERVATIONAL

Enrollment

592

Conditions

Classical Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Primary Mediastinal B Cell Lymphoma High-grade B-cell Lymphoma Burkitt Lymphoma Follicular Lymphoma Mantle Cell Lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

INCLUSION CRITERIA 1. Patients having a confirmed diagnosis of either: A) Hodgkin lymphoma B) Aggressive B-cell lymphoma (e.g. Burkitt's lymphoma, diffuse large B-cell lymphoma, grade 3b follicular lymphoma, de novo transformed follicular lymphoma) C) Indolent B-cell lymphoma (e.g. all grades of follicular lymphoma except grade 3b, marginal zone lymphoma, lymphoplasmacytic lymphoma, chronic or small lymphocytic lymphoma, mantle cell lymphoma) D) Mature T/NK-cell malignancy (any subtype) 2. Patient must be ≥ 18 years. 3. Patients will have provided written Informed Consent. EXCLUSION CRITERIA 1\) Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consent.

Locations (9)

Bedfordshire Hospitals NHS Foundation Trust

Bedford, Bedfordshire, United Kingdom

Portsmouth Hospitals University NHS Trust

Portsmouth, Hampshire, United Kingdom

University Hospital Southampton NHS Foundation Trust

Southampton, Hampshire, United Kingdom

Wye Valley NHS Trust

Hereford, Herefordshire, United Kingdom

University Hospitals of Leicester NHS Trust

Leicester, Leicestershire, United Kingdom

Norfolk and Norwich University Hospitals NHS Foundation Trust

Norwich, Norfolk, United Kingdom

Nottingham University Hospitals NHS Trust

Nottingham, Nottinghamshire, United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, Oxfordshire, United Kingdom

The Newcastle Upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, Tyne and Wear, United Kingdom

Outcomes

Primary Outcomes

Serum IgG levels against SARS-CoV-2 post-COVID-19 vaccination and change over time.

To evaluate the robustness and persistence of anti-S IgG levels.

Time frame: 12 months

Secondary Outcomes

Comparison between SARS-CoV-2 IgG responses with clinical parameters.

Correlation between anti-S IgG between different lymphoma subtypes and the impact of treatment.

Time frame: 12 months

Symptomatic COVID-19 with positive SARS-CoV-2 PCR results.

To assess the incidence of symptomatic, virologically proven COVID-19 in vaccinated individuals within 12 months of vaccine administration.

Time frame: 12 months